1. Home
  2. CDXS

as 05-20-2024 9:31am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Industrials

Major Chemicals

Nasdaq

Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.

Founded: 2002 Country:
United States
United States
Employees: N/A City: REDWOOD CITY
Market Cap: 261.1M IPO Year: 2010
Target Price: $7.50 AVG Volume (30 days): 598.6K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.93 EPS Growth: N/A
52 Week Low/High: $1.45 - $4.91 Next Earning Date: 05-02-2024
Revenue: $74,234,000 Revenue Growth: -36.13%
Revenue Growth (this year): -4.92% Revenue Growth (next year): -5.09%

Share on Social Networks:

Stock Insider Trading Activity of Codexis Inc. (CDXS)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Dorgan Byron L CDXS Director Nov 15 '23 Sell $2.11 20,000 $42,168.00 193,461 SEC Form 4